DHR — Danaher Corporation

Is DHR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of August 19, 2026

Danaher Corporation (DHR) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $211.79. The rating moved from Neutral to Overbought on August 19, 2026.

See all overbought Healthcare stocks →

AI analysis

Danaher combines a diversified diagnostics and life‑sciences portfolio with recurring consumables and services that support steady cash flow and margin durability. Ongoing secular tailwinds in biologics, gene‑therapy and diagnostics/screening create multiple organic growth levers while a disciplined M&A track record can accelerate capability expansion. Near‑term market conditions appear balanced, leaving company‑specific execution and end‑market demand as primary drivers. Key risks include competitive intensity, acquisition valuation and integration outcomes, reimbursement dynamics, and capital‑spending cyclicality. If the company sustains revenue resilience and integrates bolt‑on assets effectively, the outlook supports continued moderate upside; conversely, any material slowdown in lab capex or mispriced M&A could weigh on performance.

Key factors

  • Leading diversified life‑sciences and diagnostics portfolio with recurring consumables, instruments, and services revenue that supports margin resilience and predictable cash flow.
  • Direct exposure to accelerating demand for biologics, gene‑therapy and viral‑vector manufacturing, and analytical testing—sector themes that should benefit Danaher's tools, bioprocessing and CDMO/CRO‑oriented businesses.
  • History of execution on inorganic growth and integration capabilities that expand end‑market reach and technology breadth.
  • Product and workflow integration across diagnostics and laboratory segments supports stickier customer relationships and recurring aftermarket revenue.
  • Relative defensive demand profile amid mixed macro sentiment—diagnostics and essential lab services often show steadier spend compared with cyclical capital equipment.
  • Strong free‑cash‑flow generation enables continued share repurchases, debt management, and bolt‑on M&A to supplement organic growth.

Risks

  • Intense competition from large peers (e.g., Thermo Fisher, Roche, Agilent) that can pressure pricing, share, and acquisition opportunities.
  • Integration risk and elevated acquisition multiples could compress returns if future deals are expensive or synergies underperform expectations.
  • Reimbursement pressure and payer dynamics that can affect diagnostic volumes and pricing for certain products and services.
  • Cyclicality in capital equipment purchasing and potential pullback in lab capex during macro weakness or tighter funding for research institutions.
  • Supply‑chain, component shortages, or manufacturing disruption that could delay shipments and strain customer relations.
  • Foreign‑exchange exposure and macro uncertainty that can impact reported growth and margin trends in the near term.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for DHR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.